AVIR · Atea Pharmaceuticals Inc
United States · RS rating 38 · As of 2026-11-03
| Price | 4.17 USD |
|---|---|
| 1-day change | +1.7% |
| RS rating (overall / 1M / 3M / 12M) | 38 / 23 / 42 / 74 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 23 / 34 / 9 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -7.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +32.2% |
| Market cap (USD) | $439.8M |